0. DOCID:16003 SCORE: 0.000250023976473358
DOCNO: 1826844
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: methods
AUTHOR: R Karel-Brant R
PUBTYPE: Journal Article
JOURNALTITLE: Dermatology nursing / Dermatology Nurses' Association.
COUNTRY: UNITED STATES
TITLE: Periorbital skin cancers.
PUBDATE: 19910401
Mohs surgery is an excellent treatment for removal of periorbital skin cancers. Important structures and surrounding tissue may be preserved with this technique.

1. DOCID:19587 SCORE: 0.000250023821599849
DOCNO: 1736473
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genital Neoplasms, Male
DESCRIPTOR: Penile Neoplasms
DESCRIPTOR: Precancerous Conditions
DESCRIPTOR: Scrotum
AUTHOR: P F Schellhammer PF
AUTHOR: G H Jordan GH
AUTHOR: E L Robey EL
AUTHOR: J T Spaulding JT
AFFILIATION: Department of Urology, Eastern Virginia Medical School, Norfolk.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Urologic clinics of North America.
COUNTRY: UNITED STATES
TITLE: Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum.
PUBDATE: 19920201
Premalignant lesions of the penis include cutaneous horn, balanitis xerotica obliterans, and leukoplakia. The true incidence of progression of each of these to squamous-cell carcinoma is unknown. Bowenoid papulosis, erythroplasia of Queyrat, and Bowen's disease are histologically identical to in situ carcinoma. Although the first is consistently benign, the latter two regularly evolve into invasive cancer. Malignant scrotal lesions include squamous-cell carcinoma, liposarcoma, leiomyosarcoma, basal-cell carcinoma, extramammary Paget's disease, erythroplasia of Queyrat, malignant melanoma, and metastases. Hemangioma can be confused with carcinoma.

2. DOCID:19300 SCORE: 0.000250021759025964
DOCNO: 8094712
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Amplification
QUALIFIER: genetics
QUALIFIER: genetics
QUALIFIER: therapeutic use
AUTHOR: U Lönn U
AUTHOR: S Lönn S
AUTHOR: B Stenkvist B
AFFILIATION: Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
PUBTYPE: Journal Article
JOURNALTITLE: International journal of cancer. Journal international du cancer.
COUNTRY: UNITED STATES
TITLE: Reduced occurrence of mdr-1 amplification in stage-IV breast-cancer patients treated with tamoxifen compared with other endocrine treatments.
PUBDATE: 19930201
Amplification of mdr-1 occurs in breast cancer patients receiving endocrine treatment. We have compared a group of patients receiving tamoxifen and a group receiving second-line endocrine treatment after failure of tamoxifen treatment. Chronological tumor samples were obtained by fine-needle biopsies from the same tumor lesion of each patient and PCR was used to detect the appearance of gene amplification. Three of 20 patients receiving tamoxifen developed amplified mdr-1 whereas 7 of 17 patients receiving second-line endocrine treatment developed mdr-1 amplification.

3. DOCID:16005 SCORE: 0.00025002009188577
DOCNO: 8487233
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemically induced
QUALIFIER: adverse effects
QUALIFIER: adverse effects
AUTHOR: P J Maguire PJ
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Journal of reproductive medicine.
COUNTRY: UNITED STATES
TITLE: Estrogen replacement therapy and breast cancer.
PUBDATE: 19930301
The safety of estrogen use in breast cancer patients is discussed. Most reports indicate there is no risk.

4. DOCID:21934 SCORE: 0.000250017121683647
DOCNO: 8854585
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: pathology
QUALIFIER: diagnosis
QUALIFIER: pathology
QUALIFIER: complications
AUTHOR: E Ichikawa E
AUTHOR: S Asano S
AUTHOR: S Okabe S
AUTHOR: M Itami M
AUTHOR: K Ohara K
AFFILIATION: Department of Dermatology, Doai Memorial Hospital, Tokyo, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of dermatology.
COUNTRY: JAPAN
TITLE: A case of cutaneous malignant fibrous histiocytoma.
PUBDATE: 19960801
A 54-year-old Japanese man with cutaneous malignant fibrous histiocytoma on the back is reported. He not only had a past history of thyroid cancer 1 year prior to the onset of the skin tumor, but also had simultaneous bladder cancer. Despite the early, wide resection, the prognosis was rapid and progressive. Histologically, the primary lesion of the skin tumor was difficult to differentiate from dermatofibrosarcoma protuberans; however, the recurrent and the metastatic lesions changed in appearance.

5. DOCID:18816 SCORE: 0.000250015772396121
DOCNO: 2043699
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: immunology
QUALIFIER: immunology
AUTHOR: C Naftzger C
AUTHOR: A N Houghton AN
AFFILIATION: Memorial Sloan-Kettering Cancer Center, New York, New York.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in oncology.
COUNTRY: UNITED STATES
TITLE: Tumor immunology.
PUBDATE: 19910201
The underlying premise of tumor immunology is that the immune system is capable of recognizing cancer cells and that immune recognition can lead to rejection of tumors by the host. We focus on recent advances in tumor immunology in experimental systems, including the molecular identification of tumor antigens, studies of recognition of tumor cells by the immune system, and the development of new strategies for treatment of cancer. Identifying potential target antigens on tumors and defining effector arms of the immune system that mediate tumor rejection (including T cells, natural killer cells, antibodies, complement cells, and cytokines) remain crucial problems for the field.

6. DOCID:22472 SCORE: 0.000250013221190593
DOCNO: 8531380
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Drug Resistance, Neoplasm
QUALIFIER: chemistry
QUALIFIER: physiology
AUTHOR: T Tsuruo T
AFFILIATION: Institute of Molecular and Cellular Biosciences, University of Tokyo.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting]
PUBDATE: 19951001
Resistance of tumors to a variety of chemotherapeutic agents presents a major problem in cancer treatment. The gene responsible for multidrug resistance, termed mdr1, encodes a membrane glycoprotein (P-glycoprotein) that acts as a pump to transport various cytotoxic agents. The P-glycoprotein has been shown to bind anticancer drugs and several resistance-reversing agents including calcium channel blockers, and to be an ATPase. The P-glycoprotein was found to function in blood-brain barrier. The implication of the P-glycoprotein in relation to therapy is discussed.

7. DOCID:17351 SCORE: 0.000250012437959484
DOCNO: 1919352
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: pathology
QUALIFIER: secondary
AUTHOR: S Elango S
AUTHOR: B A Kareem BA
AUTHOR: S Chandrasekaran S
AUTHOR: N Azman N
AFFILIATION: School of Medical Sciences (USM), Kota Bharu, Malaysia.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of laryngology and otology.
COUNTRY: ENGLAND
TITLE: Nasopharyngeal carcinoma with spinal secondaries.
PUBDATE: 19910901
Nasopharyngeal carcinoma has been reported to have a higher incidence of distant metastases as compared to other head and neck cancers. Distant metastases of nasopharyngeal carcinoma has been reported in the bones, lungs, liver, distant lymph nodes, brain and porta hepatis. This report presents a case of nasopharyngeal carcinoma with secondaries in the extradural space at the thoracic level of the spinal cord which hitherto has been an unreported site.

8. DOCID:18927 SCORE: 0.000250011994995001
DOCNO: 8157474
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: T R Jenkins TR
AUTHOR: C Tangen C
AUTHOR: J S Macdonald JS
AUTHOR: G Weiss G
AUTHOR: R Chapman R
AUTHOR: A Hantel A
AFFILIATION: Brooke Army Medical Center, San Antonio, TX.
PUBTYPE: Clinical Trial
PUBTYPE: Clinical Trial, Phase II
PUBTYPE: Journal Article
JOURNALTITLE: Investigational new drugs.
COUNTRY: UNITED STATES
TITLE: A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
PUBDATE: 19931101
Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.

9. DOCID:20169 SCORE: 0.000250011614300079
DOCNO: 9538660
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: blood
QUALIFIER: enzymology
QUALIFIER: diagnosis
AUTHOR: K Ciechanowski K
AUTHOR: D Cebula D
AFFILIATION: Zakładu Biochemi Klinicznej i Diagnostyki Laboratoryjnej PAM w Szczecinie.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.
COUNTRY: POLAND
TITLE: [Two cases of Lambert-Eaton syndrome with an increase of serum cholinesterase activity]
PUBDATE: 19970201
Paraneoplastic Lambert-Eaton myasthenia syndrome is presented in two cases with small cell lung cancer. An increase of serum cholinesterase activity was explained by induced release of biologically active proteins by neoplastic tissue.

10. DOCID:20370 SCORE: 0.000250011593987778
DOCNO: 9363063
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Lung Neoplasms
DESCRIPTOR: Mediastinal Neoplasms
QUALIFIER: secondary
AUTHOR: R S Tharratt RS
AFFILIATION: University of California, Davis, School of Medicine, Sacramento, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in pulmonary medicine.
COUNTRY: UNITED STATES
TITLE: Intrathoracic neoplasms other than bronchogenic carcinoma.
PUBDATE: 19950701
Intrathoracic neoplasms other than lung cancer represent a diverse group of diseases. This review focuses on the recent literature addressing mediastinal neoplasms, unusual primary lung neoplasms, and pulmonary metastases from other locations. Advances in classification, imaging, diagnosis, surgical issues, and treatment issues shown in case series and individual case reports are presented and discussed.

11. DOCID:19017 SCORE: 0.000250011456375188
DOCNO: 8475587
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: adverse effects
AUTHOR: I R Pedersen IR
AUTHOR: M T Corfitsen MT
AUTHOR: A M Lebech AM
AUTHOR: H H Kaae HH
AFFILIATION: Kirurgisk afdeling, Rigshospitalet, København.
PUBTYPE: Journal Article
JOURNALTITLE: Ugeskrift for laeger.
COUNTRY: DENMARK
TITLE: [Complications of second-look surgery for ovarian cancer]
PUBDATE: 19930301
All complications were registered in 139 consecutive second-look operations for ovarian cancer. Forty-one complications were registered in 33 patients, none lethal. The most frequent complications were anaemia requiring blood-transfusion (10.7%) and acute cystitis (4.3%). Other complications were seen with frequencies between 0.7 to 2.8 percent. No differences with respect to complications were found between patients with residual tumour versus those without, nor between patients where only biopsies were taken versus those who had organs removed. Although the patients were in clinical complete remission, 53% were found to have residual disease at second-look operation.

12. DOCID:20032 SCORE: 0.000250011422708205
DOCNO: 9257068
AUTHOR: D Machin D
AFFILIATION: Medical Research Council Cancer Trials Office, Cambridge, United Kingdom.
PUBTYPE: Journal Article
JOURNALTITLE: Controlled clinical trials.
COUNTRY: UNITED STATES
TITLE: Assessing quality of life in comparative cancer clinical trials: does it make a difference?
PUBDATE: 19970801
Many randomized Phase III trials of cancer therapy involve quality of life assessments. This paper argues for graphical presentation of quality of life measures in order to visualize changes over time.

13. DOCID:18406 SCORE: 0.000250010940505156
DOCNO: 8474424
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: MMWR. Morbidity and mortality weekly report.
COUNTRY: UNITED STATES
TITLE: Impact of the expanded AIDS surveillance case definition on AIDS case reporting--United States, first quarter, 1993.
PUBDATE: 19930401
On January 1, 1993, the acquired immunodeficiency syndrome (AIDS) surveillance case definition for adolescents and adults was expanded beyond the surveillance definition published in 1987 (1) to include all human immunodeficiency virus (HIV)-infected persons with severe immunosuppression (< 200 CD4+ T-lymphocytes/microL or a CD4+ T-lymphocyte percentage of total lymphocytes of < 14), pulmonary tuberculosis (TB), recurrent pneumonia, or invasive cervical cancer. This report reviews AIDS surveillance reports CDC received from local, state, and territorial health departments during the first quarter of 1993 and summarizes the impact of the changes in the AIDS surveillance case definition.

14. DOCID:17071 SCORE: 0.000250010507259329
DOCNO: 1673219
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: therapy
QUALIFIER: mortality
QUALIFIER: surgery
QUALIFIER: methods
AUTHOR: T Böttger T
AUTHOR: J Klupp J
AUTHOR: K Sorger K
AUTHOR: T Junginger T
AFFILIATION: Klinik und Poliklinik für Allgemein- und Abdominalchirurgie, Johannes-Gutenberg-Universität Mainz.
PUBTYPE: Journal Article
JOURNALTITLE: Medizinische Klinik (Munich, Germany : 1983)
COUNTRY: GERMANY
TITLE: [Therapy and prognosis of medullary thyroid cancer]
PUBDATE: 19910101
Medullary thyroid cancers have different morphological, endocrine and biological qualities than all the other tumors of the thyroid. Therapy is the thyroidectomy with modified, radical neck dissection. The ten year survival rate was 65% in our own patient material. The prognosis depended on tumor size, invasion of vessels by the tumor, grade of differentiation, tumor stage, metastasis and radicality of the operation.